BOSTON, Aug. 29, 2014 /PRNewswire/ -- Vittamed Corporation, a neurodiagnostics medical device company based in Boston announced today that T. (Teo) Forcht Dagi, MD, DmedSc, MPH, MBA, FACS, FRCSEd was appointed to the company's Board of Directors.
"Teo Forcht Dagi is an experienced leader with a distinguished career in neurosurgery, medical innovation and venture capital," said Remis Bistras, President and CEO of Vittamed. "We are extremely delighted to add his clinical, strategic, and entrepreneurial expertise to our Board."
Dr. Dagi is a board certified neurosurgeon trained at the Massachusetts General Hospital. He holds faculty appointments at Harvard Medical School and Queen's University Belfast. He served as President of the Georgia Neurosurgical Society and as a Director of the American Association of Neurological Surgeons. He has sat on numerous public and private boards, has been involved in many start-ups and early stage companies, and served as a partner at and advisor to prominent venture capital funds.
"I am honored to join Vittamed at this exciting time in its history," said Dr. Dagi. "With the recent CE mark approval for both its products and multiple near-term commercial opportunities, I look forward to helping Vittamed achieve its mission of delivering non-invasive neuromonitoring and diagnostics to patients with unmet medical needs."
He received an AB from Columbia, and an MD and MPH from Johns Hopkins. He holds an MBA with distinction from Wharton and was awarded a DMedSc (Honoris Causae) from Queen's University Belfast for contributions to medicine and public service.
Vittamed is a Boston-based company with R&D operations in Lithuania. Using ultrasound based technology, it has developed a suite of clinically proven and validated devices. The Vittamed 205 is a non-invasive Intracranial Pressure (ICP) meter and the Vittamed 505 is a non-invasive Cerebrovascular Perfusion and Autoregulation monitoring device. Multiple prospective clinical trials with several hundred patients have proven that the Vittamed devices deliver reliable, clinically acceptable, accurate and precise results as compared to today's standard of care using invasive intraventricular and lumbar puncture ICP measurements. Recently Vittamed received CE mark for its both devices and is preparing for commercialization in the EU as well as 510 (k) filing in the US.
For more information, please visit www.vittamed.com
|SOURCE Vittamed Corporation|
Copyright©2014 PR Newswire.
All rights reserved